Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to select an optimal dose of taribavirin by comparing the
efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin
800 to 1400 mg/day based on body weight, both administered in combination with peginterferon
alfa-2b to therapy-naive patients with chronic Hepatitis C Virus (HCV) genotype 1 infection.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.